|
⚲
|
| Keyboard |
| Oncology Impact Private Investment Fund 2 LP
✚
|
|
|---|---|
| CIK # | 0002104306 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 3 | [0002104306] | |
| 4 | [0002104306] |
| Form 3/4/5 Subject | 2011 - 2026 |
|---|---|
| Oncology Impact Private Investment Fund 2 LP | |
| MPM Asset Management LLC | |
| Gadicke Ansbert | |
| Aktis Oncology Inc |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Aktis Oncology Inc AKTS
Common Stock
|
2026-01-12 | Conversion | 1,314,262 | ||
|
Aktis Oncology Inc AKTS
Common Stock
|
2026-01-12 | Buy | 1,112,777 | $18.00 | 20,029,986 |
|
Aktis Oncology Inc AKTS
Common Stock
|
2026-01-12 | Conversion | 1,577,119 | ||
|
Aktis Oncology Inc AKTS
Common Stock
|
2026-01-12 | Conversion | 5,914,197 | ||
|
Aktis Oncology Inc AKTS
Series B Redeemable Convertible Preferred Stock · derivative
|
2026-01-12 | Conversion | 6,000,000 | $0.00 | |
|
Aktis Oncology Inc AKTS
Series Seed Redeemable Convertible Preferred Stock · derivative
|
2026-01-12 | Conversion | 5,000,000 | $0.00 | |
|
Aktis Oncology Inc AKTS
Series A Redeemable Convertible Preferred Stock · derivative
|
2026-01-12 | Conversion | 22,500,000 | $0.00 |